

Scott Friedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7745068/publications.pdf>

Version: 2024-02-01

461
papers

66,585
citations

764

119
h-index

813

246
g-index

488
all docs

488
docs citations

488
times ranked

57031
citing authors

#	ARTICLE	IF	CITATIONS
1	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. <i>Gastroenterology</i> , 2023, 165, 5-10.	0.6	59
2	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
3	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
4	Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis. <i>Liver Transplantation</i> , 2022, 28, 27-38.	1.3	16
5	Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies. <i>Journal of Internal Medicine</i> , 2022, 291, 11-31.	2.7	45
6	Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. <i>Hepatology</i> , 2022, 75, 473-488.	3.6	169
7	Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1701-1716.	2.3	12
8	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	0.6	17
9	Fighting Cardiac Fibrosis with CAR T Cells. <i>New England Journal of Medicine</i> , 2022, 386, 1576-1578.	13.9	10
10	Genetic Characterization of Rat Hepatic Stellate Cell Line HSC-T6 for In Vitro Cell Line Authentication. <i>Cells</i> , 2022, 11, 1783.	1.8	11
11	The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells. <i>Cell Metabolism</i> , 2021, 33, 242-257.	7.2	173
12	Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6. <i>Hepatology Communications</i> , 2021, 5, 177-188.	2.0	39
13	Fully automated prediction of liver fibrosis using deep learning analysis of gadoxetic acid-enhanced MRI. <i>European Radiology</i> , 2021, 31, 3805-3814.	2.3	37
14	Activation of Hepatic Stellate Cells Requires Dissociation of E-Cadherin-Containing Adherens Junctions with Hepatocytes. <i>American Journal of Pathology</i> , 2021, 191, 438-453.	1.9	12
15	Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 5-5.	1.5	6
16	Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of <i>Erysipelotrichales</i> . <i>PLoS ONE</i> , 2021, 16, e0244763.	1.1	30
17	Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. <i>European Radiology</i> , 2021, 31, 4804-4812.	2.3	7
18	Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 329-338.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. <i>Gastroenterology</i> , 2021, 160, 1502-1520.e1.	0.6	58
20	Mechanisms and disease consequences of nonalcoholic fatty liver disease. <i>Cell</i> , 2021, 184, 2537-2564.	13.5	757
21	Aramchol downregulates stearyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. <i>JHEP Reports</i> , 2021, 3, 100237.	2.6	32
22	Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis. <i>Hepatology</i> , 2021, 74, 543-546.	3.6	7
23	Murine deficiency of peroxisomal l-bifunctional protein (EHHADH) causes medium-chain 3-hydroxydicarboxylic aciduria and perturbs hepatic cholesterol homeostasis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5631-5646.	2.4	15
24	Anti- $\text{TNF}\alpha$ treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. <i>Liver International</i> , 2021, 41, 2646-2658.	1.9	7
25	MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. <i>Abdominal Radiology</i> , 2021, 46, 5142-5151.	1.0	5
26	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	1.8	27
27	The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1419-1433.	1.7	12
28	Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 2652-2669.	3.6	95
29	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	1.8	111
30	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	15.2	98
31	Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabd1206.	5.8	24
32	Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice. <i>Nutrients</i> , 2021, 13, 3700.	1.7	5
33	Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 20827.	1.6	7
34	Title is missing!. , 2021, 16, e0244763.		0
35	Title is missing!. , 2021, 16, e0244763.		0
36	Title is missing!. , 2021, 16, e0244763.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2021, 16, e0244763.		0
38	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. American Journal of Transplantation, 2020, 20, 220-230.	2.6	33
39	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	1.9	12
40	Noninvasive point-of-care 13C-Methacetin Breath Test (MBT) predicts risk of clinical deterioration independently of currently used prognostic indicators in patients with decompensated NASH cirrhosis. Journal of Hepatology, 2020, 73, S139-S140.	1.8	0
41	Hepatic fibrosis: A convergent response to liver injury that is reversible. Journal of Hepatology, 2020, 73, 210-211.	1.8	40
42	Acute Liver Injury and Decompensated Cirrhosis. Medical Clinics of North America, 2020, 104, 647-662.	1.1	21
43	Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitis. Liver International, 2020, 40, 2172-2181.	1.9	3
44	Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132.	13.7	483
45	Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. Developmental Cell, 2020, 53, 677-690.e4.	3.1	25
46	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clinical and Translational Gastroenterology, 2020, 11, e00131.	1.3	68
47	Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver. Cells, 2020, 9, 452.	1.8	8
48	A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Reports, 2020, 2, 100064.	2.6	29
49	Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation. Hepatology, 2020, 71, 1150-1153.	3.6	1
50	Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatology Communications, 2020, 4, 953-972.	2.0	93
51	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology, 2019, 157, 1383-1397.e11.	0.6	62
52	Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. Experimental Hematology, 2019, 79, 16-25.e3.	0.2	8
53	New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Current Opinion in Pharmacology, 2019, 49, 60-70.	1.7	49
54	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology, 2019, 70, 2107-2122.	3.6	26

#	ARTICLE	IF	CITATIONS
55	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. <i>Journal of Hepatology</i> , 2019, 70, 458-469.	1.8	173
56	Hepatic Autophagy Deficiency Compromises Farnesoid X Receptor Functionality and Causes Cholestatic Injury. <i>Hepatology</i> , 2019, 69, 2196-2213.	3.6	45
57	Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor α -Retinoid X Receptor β Coactivator. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	9
58	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
59	Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells. <i>Life Sciences</i> , 2018, 203, 39-47.	2.0	20
60	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. <i>Journal of Hepatology</i> , 2018, 69, 385-395.	1.8	330
61	Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1 α -7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 137-155.	1.2	16
62	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
63	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	1.8	506
64	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
65	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. <i>Nature Communications</i> , 2018, 9, 4962.	5.8	111
66	Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 920-924.	0.2	0
67	A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease. <i>World Journal of Nephrology</i> , 2018, 7, 96-107.	0.8	2
68	SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. <i>Scientific Reports</i> , 2018, 8, 17905.	1.6	30
69	Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018, 24, 908-922.	15.2	2,392
70	A Sabbatical: The Gift That Keeps on Giving. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 656-658.	2.3	5
71	Liver fibrogenesis. , 2017, , 110-122.e5.		0
72	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. <i>Scientific Reports</i> , 2017, 7, 42563.	1.6	29

#	ARTICLE	IF	CITATIONS
73	Hepatic stellate cells as key target in liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 27-42.	6.6	943
74	Mechanisms of hepatic stellate cell activation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 397-411.	8.2	1,821
75	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
76	Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. <i>Liver International</i> , 2017, 37, 1887-1896.	1.9	52
77	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	0.6	838
78	Megatrends in bile acid receptor research. <i>Hepatology Communications</i> , 2017, 1, 831-835.	2.0	2
79	Kruppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury. <i>Scientific Reports</i> , 2017, 7, 8119.	1.6	29
80	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. <i>Experimental and Molecular Medicine</i> , 2017, 49, e396-e396.	3.2	61
81	SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. <i>EMBO Molecular Medicine</i> , 2017, 9, 1696-1710.	3.3	38
82	Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 53-67.e3.	0.6	61
83	Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 702-714.	1.8	52
84	Cell Death and Autophagy in Hepatic Stellate Cell Activation and Function. , 2017, , 39-52.		0
85	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. <i>World Journal of Virology</i> , 2017, 6, 59-72.	1.3	7
86	The Transcriptional Activator Kruppel-like Factor-6 Is Required for CNS Myelination. <i>PLoS Biology</i> , 2016, 14, e1002467.	2.6	31
87	Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0158156.	1.1	258
88	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , 2016, 63, 1875-1887.	3.6	50
89	Risk Factors for Hepatocellular Carcinoma in Cirrhotic Patients with Chronic Hepatitis B. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 535-543.	0.3	18
90	Reply. <i>Hepatology</i> , 2016, 64, 2266-2267.	3.6	0

#	ARTICLE	IF	CITATIONS
91	Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. <i>Liver International</i> , 2016, 36, 659-666.	1.9	54
92	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F352-F361.	1.3	15
93	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
94	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. <i>Scientific Reports</i> , 2016, 6, 39342.	1.6	77
95	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	0.8	178
96	PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. <i>Nature Communications</i> , 2016, 7, 12502.	5.8	162
97	Devilish Effects of Taz in Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2016, 24, 771-772.	7.2	3
98	A physician-scientist's wish list for the 2016 U.S. presidential candidates. <i>Science Translational Medicine</i> , 2016, 8, 351ed11.	5.8	0
99	Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. <i>Journal of Hepatology</i> , 2016, 65, 344-353.	1.8	30
100	Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells. <i>Fibrogenesis and Tissue Repair</i> , 2016, 9, 2.	3.4	19
101	Induction and contribution of beta platelet-derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice. <i>Liver International</i> , 2016, 36, 874-882.	1.9	14
102	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016, 65, 1754-1764.	6.1	108
103	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
104	The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. <i>Genes and Development</i> , 2016, 30, 786-797.	2.7	78
105	Antifibrotic Therapies: Where Are We Now?. <i>Seminars in Liver Disease</i> , 2016, 36, 087-098.	1.8	75
106	Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. <i>Angiogenesis</i> , 2016, 19, 155-171.	3.7	52
107	CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. <i>Cellular Signalling</i> , 2016, 28, 34-42.	1.7	45
108	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1619-1628.	2.4	47

#	ARTICLE	IF	CITATIONS
109	Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016, 22, 2844.	1.4	5
110	The future of hepatology: Embrace change. <i>Clinical Liver Disease</i> , 2015, 5, 127-128.	1.0	0
111	The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	43
112	L59 TGF- β 2 LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. <i>Fibrogenesis and Tissue Repair</i> , 2015, 8, 17.	3.4	10
113	Principles on the path to a hepatologist's enlightenment. <i>Hepatology</i> , 2015, 62, 8-12.	3.6	0
114	Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C. <i>Molecular Medicine</i> , 2015, 21, 355-363.	1.9	5
115	Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. <i>Nature Communications</i> , 2015, 6, 6994.	5.8	86
116	Stellate Cells and Hepatic Fibrosis. , 2015, , 41-62.		13
117	Emerging and Disease-Specific Mechanisms of Hepatic Stellate Cell Activation. <i>Seminars in Liver Disease</i> , 2015, 35, 107-118.	1.8	81
118	Reply. <i>Gastroenterology</i> , 2015, 149, 1988-1989.	0.6	2
119	Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseasesâ€™U.S. Food and Drug Administration Joint Workshop. <i>Hepatology</i> , 2015, 61, 1392-1405.	3.6	288
120	Pathobiology of liver fibrosis: a translational success story. <i>Gut</i> , 2015, 64, 830-841.	6.1	739
121	Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. <i>Hepatology</i> , 2015, 62, 627-634.	3.6	60
122	β 2-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. <i>Journal of Hepatology</i> , 2015, 63, 141-147.	1.8	142
123	Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. <i>Journal of Autoimmunity</i> , 2015, 63, 76-87.	3.0	30
124	Modulation of cardiac fibrosis by KrÄ¼ppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. <i>Cardiovascular Research</i> , 2015, 107, 420-430.	1.8	37
125	Hepatic Fibrosis: Emerging Therapies. <i>Digestive Diseases</i> , 2015, 33, 504-507.	0.8	65
126	Hepatic fibrosis: Concept to treatment. <i>Journal of Hepatology</i> , 2015, 62, S15-S24.	1.8	554

#	ARTICLE	IF	CITATIONS
127	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2015, 149, 367-378.e5.	0.6	1,592
128	Epithelial Xbp1 Is Required for Cellular Proliferation and Differentiation during Mammary Gland Development. <i>Molecular and Cellular Biology</i> , 2015, 35, 1543-1556.	1.1	40
129	Inhibition of the <scp>CXCL</scp>12/<scp>CXCR</scp>4 chemokine axis with <scp>AMD</scp>3100, a <scp>CXCR</scp>4 small molecule inhibitor, worsens murine hepatic injury. <i>Hepatology Research</i> , 2015, 45, 794-803.	1.8	31
130	Alcohol and inflammatory responses: Summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meeting. <i>Alcohol</i> , 2015, 49, 1-6.	0.8	19
131	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	6.1	70
132	Clarity and Challenges in Tissue Fibrosis. , 2015, , 187-194.		2
133	Hepatitis C: Diagnosis, Management and Treatment. , 2014, , 58-77.		0
134	Hereditary Hemochromatosis. , 2014, , 167-175.		0
135	Portal Hypertensive Bleeding. , 2014, , 196-208.		0
136	Hepatitis B and D. , 2014, , 41-57.		1
137	Hepatitis A and E. , 2014, , 32-40.		0
138	Drug-Induced Liver Injury. , 2014, , 23-31.		0
139	Approach to the Patient with Jaundice. , 2014, , 13-22.		0
140	HIV/HCV and HIV/HBV Co-infections. , 2014, , 78-95.		0
141	Alpha-1 Antitrypsin Deficiency. , 2014, , 187-195.		0
142	Live Donor Transplantation Evaluation. , 2014, , 415-420.		0
143	Evaluation of Patients for Liver Transplantation. , 2014, , 405-414.		0
144	Hepatopulmonary Syndrome. , 2014, , 255-262.		0

#	ARTICLE	IF	CITATIONS
145	Portopulmonary Hypertension. , 2014, , 263-270.		0
146	Diagnosis and Management of Acute Liver Failure: A Pediatric Perspective. , 2014, , 351-364.		0
147	Nutrition in Liver Diseases. , 2014, , 344-350.		1
148	Budd-Chiari Syndrome. , 2014, , 294-300.		0
149	Portal Vein Thrombosis. , 2014, , 301-307.		0
150	Liver Lesions. , 2014, , 317-324.		0
151	Cystic Lesions of the Liver. , 2014, , 325-333.		0
152	Surgery in Patients with Liver Disease. , 2014, , 334-343.		0
153	Non-Alcoholic Fatty Liver Disease. , 2014, , 132-141.		0
154	Biliary Infections. , 2014, , 111-119.		0
155	Liver Transplantation: A Pediatric Perspective. , 2014, , 394-403.		0
156	Management of End-Stage Liver Disease in Children. , 2014, , 382-393.		0
157	Approach to Jaundice in Infancy. , 2014, , 374-381.		0
158	Liver Function Tests in Childhood. , 2014, , 365-373.		0
159	Surgical Evaluation for Liver Transplantation. , 2014, , 421-426.		0
160	Post-Operative Care of The Liver Transplantation Patient. , 2014, , 427-435.		0
161	Chronic Rejection. , 2014, , 453-461.		0
162	Primary Non-Function. , 2014, , 462-468.		2

#	ARTICLE	IF	CITATIONS
163	Ischemia Reperfusion Injury after Liver Transplantation. , 2014, , 469-476.		0
164	Vascular Complications of Liver Transplantation. , 2014, , 477-485.		0
165	Biliary Complications after Liver Transplantation. , 2014, , 486-493.		0
166	Approach to Prophylaxis and Management of Infections after Liver Transplantation. , 2014, , 494-503.		0
167	Malignancy after Liver Transplantation. , 2014, , 504-511.		0
168	Hepatitis C Post-Liver Transplantation. , 2014, , 512-520.		0
169	Recurrent Disease Post-Liver Transplantation: Autoimmune Diseases, Hepatitis B and NASH. , 2014, , 521-529.		0
170	Health Maintenance after Liver Transplantation. , 2014, , 530-537.		0
171	Approach to the Patient with Abnormal Liver Tests. , 2014, , 1-12.		0
172	Acute Rejection. , 2014, , 444-452.		0
173	Spontaneous Bacterial Peritonitis. , 2014, , 227-234.		0
174	Pregnancy-Related Liver Disease. , 2014, , 271-279.		0
175	Diagnostic Approach to Abnormal Liver Tests Following Liver Transplantation. , 2014, , 436-443.		0
176	Final and future frontiers. Journal of Hepatology, 2014, 61, 969-970.	1.8	0
177	Autoimmune Hepatitis and Overlap Syndromes. , 2014, , 142-150.		0
178	Association of Genetic Variants With Rapid Fibrosis. Transplantation, 2014, 97, 1072-1078.	0.5	4
179	Hepatic Fibrosis and the Microenvironment: Fertile Soil for Hepatocellular Carcinoma Development. Gene Expression, 2014, 16, 77-84.	0.5	56
180	Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Current Opinion in Oncology, 2014, 26, 100-107.	1.1	74

#	ARTICLE	IF	CITATIONS
181	Replacing a crystal ball with a calculator in predicting liver disease outcomes. <i>Journal of Hepatology</i> , 2014, 60, 905-906.	1.8	2
182	Focus. <i>Journal of Hepatology</i> , 2014, 60, 1-2.	1.8	17
183	Î²-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. <i>Cancer Letters</i> , 2014, 343, 90-97.	3.2	71
184	Central Role of Conventional Dendritic Cells in Regulation of Bone Marrow Release and Survival of Neutrophils. <i>Journal of Immunology</i> , 2014, 192, 3374-3382.	0.4	45
185	Hepatic Abscess. , 2014, , 96-110.		0
186	NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. <i>Nature Communications</i> , 2014, 5, 3920.	5.8	117
187	Focusing on the past, present, and future of hepatology. <i>Journal of Hepatology</i> , 2014, 61, 1196-1198.	1.8	3
188	Non-Cirrhotic Portal Hypertension. , 2014, , 308-316.		0
189	LAP degradation product reflects plasma kallikrein-dependent TGF-Î² activation in patients with hepatic fibrosis. <i>SpringerPlus</i> , 2014, 3, 221.	1.2	23
190	IL-17A Enhances the Expression of Profibrotic Genes through Upregulation of the TGF-Î² Receptor on Hepatic Stellate Cells in a JNK-Dependent Manner. <i>Journal of Immunology</i> , 2014, 193, 3925-3933.	0.4	101
191	Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. <i>Antiviral Research</i> , 2014, 107, 23-30.	1.9	115
192	Transporting pharmacogenomics into clinical practice. <i>Journal of Hepatology</i> , 2014, 61, 1-2.	1.8	12
193	“There are decades where nothing happens; and there are weeks where decades happen” Vladimir Ilyich Lenin. <i>Journal of Hepatology</i> , 2014, 60, 471-472.	1.8	2
194	Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2RÎ± ^{-/-} /Î³ mice. <i>Journal of Autoimmunity</i> , 2014, 51, 99-108.	3.0	62
195	Tracking HCC pathogenesis but not the tumor cells after biopsy. <i>Journal of Hepatology</i> , 2014, 61, 457-458.	1.8	0
196	The Immunopathogenesis of Cirrhosis. , 2014, , 413-424.		2
197	Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo. <i>Digestive Diseases and Sciences</i> , 2013, 58, 257-64.	1.1	50
198	Focus. <i>Journal of Hepatology</i> , 2013, 58, 845-846.	1.8	5

#	ARTICLE	IF	CITATIONS
199	Hepatitis Outreach Network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities. <i>Journal of Hepatology</i> , 2013, 58, 890-897.	1.8	58
200	Focus. <i>Journal of Hepatology</i> , 2013, 59, 1-2.	1.8	2
201	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. <i>Journal of Hepatology</i> , 2013, 58, 1000-1006.	1.8	50
202	Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1024-1030.	0.6	195
203	Hepatic Stellate Cells and Liver Fibrosis. , 2013, 3, 1473-1492.		561
204	Therapy for Fibrotic Diseases: Nearing the Starting Line. <i>Science Translational Medicine</i> , 2013, 5, 167sr1.	5.8	546
205	Focus. <i>Journal of Hepatology</i> , 2013, 58, 1-2.	1.8	12
206	A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. <i>Hepatology</i> , 2013, 57, 339-350.	3.6	118
207	Focus. <i>Journal of Hepatology</i> , 2013, 59, 403-404.	1.8	0
208	Focus. <i>Journal of Hepatology</i> , 2013, 59, 915-917.	1.8	0
209	Preface to BBA issue devoted to fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 865.	1.8	0
210	Autophagy and mesenchymal cell fibrogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 972-978.	1.8	16
211	Focus. <i>Journal of Hepatology</i> , 2013, 58, 407-408.	1.8	0
212	Convergent pathways that cause hepatic fibrosis in NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 71-72.	8.2	54
213	Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2013, 144, 512-527.	0.6	600
214	A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor- β^2 and vascular endothelial growth factor signalling. <i>Liver International</i> , 2013, 33, 504-515.	1.9	84
215	Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. <i>Journal of Hepatology</i> , 2013, 59, 98-104.	1.8	203
216	A Candidate Gene Study for the Association of Host Single Nucleotide Polymorphisms with Liver Cirrhosis Risk in Chinese Hepatitis B Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 681-686.	0.3	9

#	ARTICLE	IF	CITATIONS
217	Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 57, 1394-1406.	3.6	197
218	Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G364-G374.	1.6	63
219	CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G375-G382.	1.6	17
220	Vascular Injury Triggers KrÄppel-Like Factor 6 Mobilization and Cooperation With Specificity Protein 1 to Promote Endothelial Activation Through Upregulation of the Activin Receptor-Like Kinase 1 Gene. <i>Circulation Research</i> , 2013, 112, 113-127.	2.0	54
221	Functions of autophagy in normal and diseased liver. <i>Autophagy</i> , 2013, 9, 1131-1158.	4.3	384
222	Reduced hepatic stellate cell expression of kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. <i>Hepatology</i> , 2013, 57, 786-796.	3.6	37
223	Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. <i>PLoS ONE</i> , 2013, 8, e75361.	1.1	180
224	Cellular basis of hepatic fibrosis and its role in inflammation and cancer. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 217-230.	0.8	89
225	Genetic Characteristics of the Human Hepatic Stellate Cell Line LX-2. <i>PLoS ONE</i> , 2013, 8, e75692.	1.1	53
226	The Role of Chemokines in Acute Liver Injury. <i>Frontiers in Physiology</i> , 2012, 3, 213.	1.3	150
227	Fibrogenic cell reversion underlies fibrosis regression in liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9230-9231.	3.3	44
228	Discoïdin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. <i>Gut</i> , 2012, 61, 1465-1472.	6.1	66
229	Liver fibrogenesis. , 2012, , 102-112.e4.		0
230	Hepatocyte Growth Factor Enhances Alternative Splicing of the KrÄppel-like Factor 6 (KLF6) Tumor Suppressor to Promote Growth through SRSF1. <i>Molecular Cancer Research</i> , 2012, 10, 1216-1227.	1.5	57
231	The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma. <i>Current Pharmaceutical Design</i> , 2012, 19, 1262-1272.	0.9	7
232	Autophagy Releases Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human Tissues. <i>Gastroenterology</i> , 2012, 142, 938-946.	0.6	523
233	Autophagy fuels tissue fibrogenesis. <i>Autophagy</i> , 2012, 8, 849-850.	4.3	86
234	CD11b ⁺ Gr1 ⁺ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. <i>Hepatology</i> , 2012, 56, 1902-1912.	3.6	65

#	ARTICLE	IF	CITATIONS
235	Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate. <i>Liver International</i> , 2012, 32, 1008-1017.	1.9	35
236	Protect thee from the sins of thy fathers?. <i>Nature Medicine</i> , 2012, 18, 1331-1332.	15.2	3
237	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
238	Focus. <i>Journal of Hepatology</i> , 2012, 56, 1-3.	1.8	82
239	Focus. <i>Journal of Hepatology</i> , 2012, 56, 511-512.	1.8	1
240	Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012, 56, 1343-1350.	1.8	181
241	Focus. <i>Journal of Hepatology</i> , 2012, 56, 1001-1002.	1.8	2
242	Focus. <i>Journal of Hepatology</i> , 2012, 57, 1-2.	1.8	4
243	Focus. <i>Journal of Hepatology</i> , 2012, 57, 481-483.	1.8	2
244	Focus. <i>Journal of Hepatology</i> , 2012, 57, 935-936.	1.8	2
245	High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. <i>Life Sciences</i> , 2012, 91, 207-212.	2.0	27
246	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012, 56, 1361-1370.	3.6	31
247	Hepatic Fibrosis and Cirrhosis. , 2012, , 64-85.		10
248	Genomics and proteomics in liver fibrosis and cirrhosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 1.	3.4	47
249	Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1083-1093.	3.6	55
250	Fibrosis-dependent mechanisms of hepatocarcinogenesis. <i>Hepatology</i> , 2012, 56, 769-775.	3.6	338
251	Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. <i>Hepatology</i> , 2012, 55, 244-255.	3.6	119
252	Mechanisms of Liver Fibrosis Associated with Experimental <i>Fasciola hepatica</i> Infection: Roles of Fas2 Proteinase and Hepatic Stellate Cell Activation. <i>Journal of Parasitology</i> , 2011, 97, 82.	0.3	19

#	ARTICLE	IF	CITATIONS
253	Detection of a secreted metalloprotease within the nuclei of liver cells. <i>Molecular BioSystems</i> , 2011, 7, 2012.	2.9	7
254	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
255	Pathogenesis of Liver Fibrosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 425-456.	9.6	1,382
256	Scraping fibrosis: Expressway to the core of fibrosis. <i>Nature Medicine</i> , 2011, 17, 552-553.	15.2	180
257	Fibrosis as a Major Mechanism of Chronic Liver Disease. , 2011, , 91-107.		1
258	Loss of Discoidin Domain Receptor 2 Promotes Hepatic Fibrosis after Chronic Carbon Tetrachloride through Altered Paracrine Interactions between Hepatic Stellate Cells and Liver-Associated Macrophages. <i>American Journal of Pathology</i> , 2011, 179, 2894-2904.	1.9	52
259	Platelets arrive at the scene of fibrosisâ€ â€ studies. <i>Journal of Hepatology</i> , 2011, 54, 1063-1065.	1.8	5
260	Inhibition of PDGF, TGF-Î², and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. <i>Journal of Hepatology</i> , 2011, 55, 612-625.	1.8	148
261	Focus. <i>Journal of Hepatology</i> , 2011, 54, 841-843.	1.8	0
262	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
263	Focus. <i>Journal of Hepatology</i> , 2011, 55, 1-2.	1.8	4
264	Focus. <i>Journal of Hepatology</i> , 2011, 55, 503-504.	1.8	1
265	Focus. <i>Journal of Hepatology</i> , 2011, 55, 953-954.	1.8	1
266	Dendritic Cells in Alcoholic Liver Injury and Fibrosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 776-781.	1.4	9
267	Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. <i>Experimental and Molecular Pathology</i> , 2011, 91, 664-672.	0.9	48
268	Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating CollagenÎ Expression. <i>Digestive Diseases and Sciences</i> , 2011, 56, 406-416.	1.1	70
269	Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor Î²1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation. <i>Inflammation Research</i> , 2011, 60, 597-604.	1.6	24
270	Carcinogen-induced hepatic tumors in KLF6+/Î± mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011, 54, 522-531.	3.6	39

#	ARTICLE	IF	CITATIONS
271	A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. <i>Hepatology</i> , 2011, 54, 2198-2207.	3.6	27
272	Mechanisms of hepatic fibrogenesis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 195-206.	1.0	772
273	Innate immunity in alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G516-G525.	1.6	191
274	SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF- β 1 and PDGF. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G739-G748.	1.6	36
275	Amelioration of hepatic fibrosis by NK cell activation. <i>Gut</i> , 2011, 60, 90-98.	6.1	102
276	Current status of novel antifibrotic therapies in patients with chronic liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 391-417.	1.4	171
277	Obesity, Inflammatory Signaling, and Hepatocellular Carcinoma—An Enlarging Link. <i>Cancer Cell</i> , 2010, 17, 115-117.	7.7	47
278	Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. <i>FEBS Letters</i> , 2010, 584, 1006-1010.	1.3	22
279	Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. <i>Hepatology</i> , 2010, 51, 1445-1449.	3.6	436
280	Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. <i>Hepatology</i> , 2010, 52, 1008-1016.	3.6	131
281	Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). <i>Journal of Cellular Physiology</i> , 2010, 223, 648-657.	2.0	77
282	Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. <i>Fibrogenesis and Tissue Repair</i> , 2010, 3, 21.	3.4	232
283	A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. <i>Thrombosis and Haemostasis</i> , 2010, 104, 531-533.	1.8	14
284	KLF6 Gene and Early Melanoma Development in a Collagen I-Rich Extracellular Environment. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1131-1147.	3.0	12
285	Increased expression of the oncogenic <i>KLF6</i> -SV1 transcript in human glioblastoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1167-1170.	1.4	12
286	A DDX5 S480A Polymorphism Is Associated with Increased Transcription of Fibrogenic Genes in Hepatic Stellate Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 5428-5437.	1.6	32
287	Fibrosis in the Liver. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 97, 151-200.	0.9	29
288	Evolving challenges in hepatic fibrosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 425-436.	8.2	516

#	ARTICLE	IF	CITATIONS
289	Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Plays a Key Role in Stellate Cell Activation and Liver Fibrogenesis In Vivo. <i>Gastroenterology</i> , 2010, 139, 1375-1384.e4.	0.6	105
290	Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. <i>Developmental Biology</i> , 2010, 344, 79-93.	0.9	28
291	Extracellular Matrix. , 2010, , 93-104.		3
292	E3 Ubiquitin Ligase Synoviolin Is Involved in Liver Fibrogenesis. <i>PLoS ONE</i> , 2010, 5, e13590.	1.1	35
293	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. <i>Journal of Immunotoxicology</i> , 2009, 6, 266-275.	0.9	100
294	Commentary: Gastroenterology and Hepatology: An Evolving Marriage, Not an Imminent Divorce. <i>American Journal of Gastroenterology</i> , 2009, 104, 10-11.	0.2	36
295	Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 7385-7392.	0.4	978
296	Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. <i>Hepatology</i> , 2009, 49, 960-968.	3.6	201
297	Detection of novel biomarkers of liver cirrhosis by proteomic analysis. <i>Hepatology</i> , 2009, 49, 1257-1266.	3.6	132
298	p38 α -MAPK α and caspase β -mediated superoxide α -induced apoptosis of rat hepatic stellate cells: Reversal by retinoic acid. <i>Journal of Cellular Physiology</i> , 2009, 218, 157-166.	2.0	42
299	PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. <i>Laboratory Investigation</i> , 2009, 89, 209-221.	1.7	33
300	Therapeutic targeting of the PDGF and TGF- β -signaling pathways in hepatic stellate cells by PTK787/ZK22258. <i>Laboratory Investigation</i> , 2009, 89, 1152-1160.	1.7	65
301	Functional role of the KLF6 tumour suppressor gene in gastric cancer. <i>European Journal of Cancer</i> , 2009, 45, 666-676.	1.3	48
302	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
303	Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2009, 51, 750-757.	1.8	67
304	Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. <i>Gastroenterology</i> , 2009, 137, 309-319.e3.	0.6	149
305	110 MOLECULAR AND CLINICAL CHARACTERIZATION OF RICTOR (MTORC2) AS A CANDIDATE ONCOGENE IN HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2009, 50, S45.	1.8	0
306	Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. <i>Hepatology Research</i> , 2009, 39, 601-608.	1.8	36

#	ARTICLE	IF	CITATIONS
307	Hepatic fibrosis. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 223-229.	1.0	212
308	Krüppel-like Factors and the Liver. , 2009, , 141-150.		2
309	Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. <i>Journal of Immunotoxicology</i> , 2009, 00, 090924084432057-10.	0.9	59
310	Hepatic fibrosis—Overview. <i>Toxicology</i> , 2008, 254, 120-129.	2.0	301
311	Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. <i>Hepatology</i> , 2008, 48, 963-977.	3.6	131
312	Targeting siRNA to arrest fibrosis. <i>Nature Biotechnology</i> , 2008, 26, 399-400.	9.4	15
313	Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 134, 1521-1531.	0.6	96
314	Mechanisms of Hepatic Fibrogenesis. <i>Gastroenterology</i> , 2008, 134, 1655-1669.	0.6	2,381
315	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	0.6	644
316	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
317	Experimental models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 858-879.	1.8	203
318	Advances in antifibrotic therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 803-816.	1.4	81
319	Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2008, 44, 1895-1903.	1.3	41
320	Cannabinoids Provoke Alcoholic Steatosis through a Conspiracy of Neighbors. <i>Cell Metabolism</i> , 2008, 7, 187-188.	7.2	6
321	The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2008, 135, 282-291.e1.	0.6	177
322	Preface. <i>Clinics in Liver Disease</i> , 2008, 12, xiii-xiv.	1.0	21
323	Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. <i>Physiological Reviews</i> , 2008, 88, 125-172.	13.1	2,345
324	Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 475-483.	1.3	150

#	ARTICLE	IF	CITATIONS
325	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
326	Insulin-Like Growth Factor-I Regulates Krüppel-Like Factor-6 Gene Expression in a p53-Dependent Manner. <i>Endocrinology</i> , 2008, 149, 1890-1897.	1.4	18
327	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2008, 118, 2711-2721.	3.9	97
328	Divergent roles of tumor suppressor gene Klf6 in ES cell differentiation. <i>Journal of Electrophoresis</i> , 2008, 52, 65-69.	0.2	2
329	Human Hepatic Stellate Cells Carry a New Splice Variant of the Human ADAMTS13. <i>Blood</i> , 2008, 112, 4085-4085.	0.6	0
330	Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G628-G638.	1.6	29
331	Reversibility of hepatic fibrosis and cirrhosis—“is it all hype?”. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 236-237.	1.7	26
332	Hepatic Fibrogenesis. <i>Seminars in Liver Disease</i> , 2007, 27, 413-426.	1.8	110
333	Genomics and Signaling Pathways in Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2007, 27, 055-076.	1.8	491
334	Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis. <i>Gut</i> , 2007, 56, 396-404.	6.1	23
335	Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. <i>Gut</i> , 2007, 56, 706-714.	6.1	129
336	Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye. <i>Journal of Hepatology</i> , 2007, 46, 180-182.	1.8	1
337	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	1.8	75
338	Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. <i>Hepatology Research</i> , 2007, 37, 579-595.	1.8	15
339	The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. , 2007, , 111-121.		9
340	Transplantation Trends in Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1313-1315.	2.4	130
341	Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. <i>International Journal of Cancer</i> , 2007, 121, 1390-1395.	2.3	73
342	KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2007, 121, 1976-1983.	2.3	34

#	ARTICLE	IF	CITATIONS
343	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	3.6	632
344	A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 297-306.	3.6	285
345	Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. <i>Hepatology</i> , 2007, 46, 1919-1926.	3.6	236
346	A deer in the headlights: BAMBI meets liver fibrosis. <i>Nature Medicine</i> , 2007, 13, 1281-1282.	15.2	24
347	Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin. <i>Journal of the American College of Surgeons</i> , 2007, 205, S93-S94.	0.2	0
348	Liver fibrosis: from mechanisms to treatment. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 812-814.	0.9	28
349	KLF6 degradation after apoptotic DNA damage. <i>FEBS Letters</i> , 2006, 580, 6981-6986.	1.3	30
350	Identification of Two Gene Variants Associated With Risk of Advanced Fibrosis in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2006, 130, 1679-1687.	0.6	113
351	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	0.6	379
352	Diagnosis of Hepatic Fibrosis in Patients with Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2006, 10, 821-833.	1.0	16
353	Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. <i>Journal of Hepatology</i> , 2006, 45, 60-71.	1.8	242
354	Developmental regulation of yolk sac hematopoiesis by Krüppel-like factor 6. <i>Blood</i> , 2006, 107, 1357-1365.	0.6	126
355	Transcriptional regulation of stellate cell activation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, S79-S83.	1.4	38
356	CARDIOVASCULAR TOLERANCE IN UNSEATED UPPER GASTROINTESTINAL ENDOSCOPY: PROSPECTIVE RANDOMIZED COMPARISON BETWEEN TRANSNASAL AND CONVENTIONAL ORAL PROCEDURES. <i>Digestive Endoscopy</i> , 2006, 18, 282-287.	1.3	20
357	Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. <i>British Journal of Pharmacology</i> , 2006, 148, 1144-1155.	2.7	209
358	Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1391-1400.	2.2	22
359	Antifibrotic targets and therapy in HCV. <i>Current Hepatitis Reports</i> , 2006, 5, 94-100.	0.3	0
360	Reversal of hepatic fibrosis – Fact or fantasy?. <i>Hepatology</i> , 2006, 43, S82-S88.	3.6	348

#	ARTICLE	IF	CITATIONS
361	Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. <i>Hepatology</i> , 2006, 43, 435-443.	3.6	257
362	Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling. <i>Seminars in Liver Disease</i> , 2006, 26, 373-384.	1.8	48
363	Hepatic Fibrosis and Cirrhosis. , 2006, , 87-109.		8
364	Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. <i>Carcinogenesis</i> , 2006, 27, 216-224.	1.3	18
365	Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. <i>Clinical Cancer Research</i> , 2006, 12, 3730-3739.	3.2	103
366	Reply:. <i>Hepatology</i> , 2005, 41, 682-683.	3.6	11
367	Antifibrotic targets and therapy in HCV. <i>Current Hepatitis Reports</i> , 2005, 4, 61-67.	0.3	0
368	Extracellular Matrix. , 2005, , 63-71.		1
369	Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. <i>Cancer Research</i> , 2005, 65, 5761-5768.	0.4	151
370	Precision-Cut Liver Slices as a New Model to Study Toxicity-Induced Hepatic Stellate Cell Activation in a Physiologic Milieu. <i>Toxicological Sciences</i> , 2005, 85, 632-638.	1.4	85
371	Enhanced Oral Tolerance in Transgenic Mice with Hepatocyte Secretion of IL-10. <i>Journal of Immunology</i> , 2005, 175, 3577-3583.	0.4	17
372	Kruppel-like Factor-6 Promotes Preadipocyte Differentiation through Histone Deacetylase 3-dependent Repression of DLK1. <i>Journal of Biological Chemistry</i> , 2005, 280, 26941-26952.	1.6	153
373	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. <i>Cancer Research</i> , 2005, 65, 1213-1222.	0.4	202
374	Regulation of Kruppel-like Factor 6 Tumor Suppressor Activity by Acetylation. <i>Cancer Research</i> , 2005, 65, 9216-9225.	0.4	53
375	Prevention of Rat Hepatocarcinogenesis by Acyclic Retinoid Is Accompanied by Reduction in Emergence of Both TGF- β -Expressing Oval-Like Cells and Activated Hepatic Stellate Cells. <i>Nutrition and Cancer</i> , 2005, 51, 197-206.	0.9	43
376	Interleukin-6 protects hepatocytes from CCl ₄ -mediated necrosis and apoptosis in mice by reducing MMP-2 expression. <i>Journal of Hepatology</i> , 2005, 42, 548-556.	1.8	100
377	Mechanisms of Nitric Oxide Interplay with Rho GTPase Family Members in Modulation of Actin Membrane Dynamics in Pericytes and Fibroblasts. <i>American Journal of Pathology</i> , 2005, 166, 1861-1870.	1.9	79
378	Mac the knife? Macrophages – the double-edged sword of hepatic fibrosis. <i>Journal of Clinical Investigation</i> , 2005, 115, 29-32.	3.9	73

#	ARTICLE	IF	CITATIONS
379	Mac the knife? Macrophagesâ€™ the double-edged sword of hepatic fibrosis. <i>Journal of Clinical Investigation</i> , 2005, 115, 29-32.	3.9	41
380	Retinoids in Cancer Chemoprevention. <i>Current Cancer Drug Targets</i> , 2004, 4, 285-298.	0.8	127
381	Transcriptional Activation of the Insulin-Like Growth Factor I Receptor Gene by the Kruppel-Like Factor 6 (KLF6) Tumor Suppressor Protein: Potential Interactions between KLF6 and p53. <i>Endocrinology</i> , 2004, 145, 3769-3777.	1.4	56
382	Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. <i>Cancer Research</i> , 2004, 64, 3885-3891.	0.4	152
383	The RING Finger Protein, RNF8, Interacts with Retinoid X Receptor Î± and Enhances Its Transcription-stimulating Activity. <i>Journal of Biological Chemistry</i> , 2004, 279, 18926-18934.	1.6	37
384	Lhx2 ^{-/-} mice develop liver fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16549-16554.	3.3	81
385	Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. <i>Oncogene</i> , 2004, 23, 5077-5083.	2.6	84
386	Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. <i>Oncogene</i> , 2004, 23, 6942-6953.	2.6	27
387	Apoptosis: The nexus of liver injury and fibrosis. <i>Hepatology</i> , 2004, 39, 273-278.	3.6	483
388	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1047-1052.	3.6	142
389	Stellate cells: A moving target in hepatic fibrogenesis. <i>Hepatology</i> , 2004, 40, 1041-1043.	3.6	109
390	Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancerâ€™. <i>Gastroenterology</i> , 2004, 126, 1090-1103.	0.6	165
391	Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. <i>Gastroenterology</i> , 2004, 127, 870-882.	0.6	239
392	Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2004, 1, 98-105.	1.7	421
393	The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common?. <i>Journal of Hepatology</i> , 2004, 40, 1050-1052.	1.8	5
394	Prostaglandin E2 inhibits transforming growth factor Î²1-mediated induction of collagen Î±1(I) in hepatic stellate cells. <i>Journal of Hepatology</i> , 2004, 41, 251-258.	1.8	69
395	Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. <i>Hepatology</i> , 2003, 37, 87-95.	3.6	204
396	Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. <i>Hepatology</i> , 2003, 37, 674-685.	3.6	171

#	ARTICLE	IF	CITATIONS
397	Treatment of hepatic fibrosis: Almost there. <i>Current Gastroenterology Reports</i> , 2003, 5, 48-56.	1.1	39
398	Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic. <i>Laboratory Investigation</i> , 2003, 83, 655-663.	1.7	370
399	Krüppel Cripples Prostate Cancer. <i>American Journal of Pathology</i> , 2003, 162, 1047-1052.	1.9	41
400	Liver fibrosis “from bench to bedside. <i>Journal of Hepatology</i> , 2003, 38, 38-53.	1.8	1,437
401	Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. <i>Carcinogenesis</i> , 2003, 24, 1353-1359.	1.3	65
402	KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION.. <i>Journal of Investigative Medicine</i> , 2003, 51, 336-337.	0.7	0
403	Cytochrome P450 2E1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 9853-9864.	1.6	176
404	Discoidin Domain Receptor 2 Interacts with Src and Shc following Its Activation by Type I Collagen. <i>Journal of Biological Chemistry</i> , 2002, 277, 19206-19212.	1.6	118
405	Discoidin Domain Receptor 2 Regulates Fibroblast Proliferation and Migration through the Extracellular Matrix in Association with Transcriptional Activation of Matrix Metalloproteinase-2. <i>Journal of Biological Chemistry</i> , 2002, 277, 3606-3613.	1.6	205
406	Future Research Directions in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 236-246.	2.5	170
407	Transcriptional activation of endoglin and transforming growth factor- β signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. <i>Blood</i> , 2002, 100, 4001-4010.	0.6	169
408	The enlarging role of matrix metalloproteinases in liver injury “beyond scar degradation. <i>Journal of Hepatology</i> , 2002, 37, 293-294.	1.8	1
409	Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. <i>Hepatology</i> , 2002, 35, 62-73.	3.6	234
410	Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. <i>Hepatology</i> , 2002, 35, 332-340.	3.6	61
411	Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. <i>Hepatology</i> , 2002, 35, 762-771.	3.6	342
412	Synergistic induction of apoptosis by acyclic retinoid and interferon- β in human hepatocellular carcinoma cells. <i>Hepatology</i> , 2002, 36, 1115-1124.	3.6	47
413	Hepatic fibrosis--role of hepatic stellate cell activation. <i>MedGenMed: Medscape General Medicine</i> , 2002, 4, 27.	0.2	70
414	HEPATIC FIBROSIS. <i>Clinics in Liver Disease</i> , 2001, 5, 315-334.	1.0	172

#	ARTICLE	IF	CITATIONS
415	Embryonic expression of KrÄ4ppel-like factor 6 in neural and non-neural tissues. Mechanisms of Development, 2001, 106, 167-170.	1.7	43
416	KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science, 2001, 294, 2563-2566.	6.0	408
417	Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. American Journal of Physiology - Endocrinology and Metabolism, 2001, 280, E405-E412.	1.8	68
418	Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology, 2001, 33, 569-576.	3.6	100
419	Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology, 2001, 34, 55-61.	3.6	216
420	Intravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2001, 7, 1-7.	0.9	65
421	Is Liver Fibrosis Reversible?. New England Journal of Medicine, 2001, 344, 452-454.	13.9	151
422	Transcriptional Regulation in Hepatic Stellate Cells. Seminars in Liver Disease, 2001, 21, 385-396.	1.8	40
423	DDR2 receptor promotes MMP-2â€mediated proliferation and invasion by hepatic stellate cells. Journal of Clinical Investigation, 2001, 108, 1369-1378.	3.9	235
424	Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. American Journal of Physiology - Renal Physiology, 2000, 279, G7-G11.	1.6	181
425	Ethanol and Arachidonic Acid Increase Î±2(I) Collagen Expression in Rat Hepatic Stellate Cells Overexpressing Cytochrome P450 2E1. Journal of Biological Chemistry, 2000, 275, 20136-20145.	1.6	112
426	The KrÄ4ppel-like transcriptional factors Zf9 and GKLf coactivate the human keratin 4 promoter and physically interact. FEBS Letters, 2000, 473, 95-100.	1.3	64
427	Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury. Journal of Biological Chemistry, 2000, 275, 2247-2250.	1.6	1,855
428	An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. Journal of Lipid Research, 2000, 41, 882-893.	2.0	250
429	Cytokines and Fibrogenesis. Seminars in Liver Disease, 1999, 19, 129-140.	1.8	319
430	Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 618-633.	1.4	309
431	Activation of rat hepatic stellate cells leads to loss of glutathionS-transferases and their enzymatic activity against products of oxidative stress. Hepatology, 1999, 30, 927-933.	3.6	38
432	CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology, 1999, 30, 987-996.	3.6	175

#	ARTICLE	IF	CITATIONS
433	Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF- β^2 mediated fibrogenesis in vivo. <i>Journal of Hepatology</i> , 1999, 30, 1073-1080.	1.8	74
434	Molecular regulation of hepatic fibrogenesis. <i>Journal of Hepatology</i> , 1998, 29, 836-847.	1.8	238
435	SYSTEMIC AMYLOIDOSIS AND THE GASTROINTESTINAL TRACT. <i>Gastroenterology Clinics of North America</i> , 1998, 27, 595-614.	1.0	48
436	p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs. <i>Journal of Experimental Medicine</i> , 1998, 188, 2033-2045.	4.2	788
437	Cellular Networks in Hepatic Fibrosis. <i>Digestion</i> , 1998, 59, 368-371.	1.2	26
438	Transcriptional Activation of Transforming Growth Factor β^1 and Its Receptors by the Kruppel-like Factor Zf9/Core Promoter-binding Protein and Sp1. <i>Journal of Biological Chemistry</i> , 1998, 273, 33750-33758.	1.6	235
439	Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9500-9505.	3.3	234
440	Early genes induced in hepatic stellate cells during wound healing. <i>Gene</i> , 1997, 195, 235-243.	1.0	56
441	On the "True-False" Memory Syndrome: The Problem of Clinical Evidence. <i>American Journal of Psychotherapy</i> , 1997, 51, 102-122.	0.4	8
442	Downregulation of matrix and α -PDGF receptor gene expression by anti-TGF β antibody in rat hepatic stellate cells during experimental liver injury. <i>International Hepatology Communications</i> , 1997, 6, 144-152.	0.7	2
443	Molecular mechanisms of hepatic fibrosis and principles of therapy. <i>Journal of Gastroenterology</i> , 1997, 32, 424-430.	2.3	123
444	Differential expression of transforming growth factor- β^2 isoforms and receptors in experimental membranous nephropathy. <i>Kidney International</i> , 1996, 50, 116-124.	2.6	89
445	Parenchymal FE and collagen gene expression: An iron-clad association?. <i>Hepatology</i> , 1995, 21, 1197-1199.	3.6	8
446	Excess iron into hepatocytes is required for activation of collagen I gene during experimental siderosis Gualdi R, Casalgrandi G, Moniosi G, Ventura E, Pietrangelo A. <i>Gastroenterology</i> 107:1118-1234, 1994. <i>Hepatology</i> , 1995, 21, 1197-1199.	3.6	4
447	The Cellular Basis of Hepatic Fibrosis – Mechanisms and Treatment Strategies. <i>New England Journal of Medicine</i> , 1993, 328, 1828-1835.	13.9	1,377
448	Parenchymal and Nonparenchymal Cell Interactions in the Liver. <i>Seminars in Liver Disease</i> , 1993, 13, 13-20.	1.8	49
449	Neoplasms of the Gastrointestinal Tract and Hepatobiliary System in Acquired Immunodeficiency Syndrome. <i>Seminars in Liver Disease</i> , 1992, 12, 128-141.	1.8	25
450	Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture. <i>Hepatology</i> , 1992, 15, 234-243.	3.6	264

#	ARTICLE	IF	CITATIONS
451	“Cuts both ways”: Collagenases, lipocyte activation and polyunsaturated lecithin. <i>Hepatology</i> , 1992, 15, 549-551.	3.6	10
452	Inhibition of rat hepatic lipocyte activation in culture by interferon- β . <i>Hepatology</i> , 1992, 16, 776-784.	3.6	180
453	Cytoskeleton of liver perisinusoidal cells (lipocytes) in normal and pathological conditions. <i>Cytoskeleton</i> , 1992, 22, 227-234.	4.4	26
454	Kaposi's sarcoma and lymphoma of the gut in AIDS. <i>Bailliere's Clinical Gastroenterology</i> , 1990, 4, 455-475.	0.9	23
455	Connective tissue biology and hepatic fibrosis: Report of a conference. <i>Hepatology</i> , 1990, 11, 488-498.	3.6	119
456	Acetaldehyde and alcoholic fibrogenesis: Fuel to the fire, but not the spark. <i>Hepatology</i> , 1990, 12, 609-612.	3.6	30
457	Cellular Sources of Collagen and Regulation of Collagen Production in Liver. <i>Seminars in Liver Disease</i> , 1990, 10, 20-29.	1.8	194
458	Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. <i>Analytical Biochemistry</i> , 1987, 161, 207-218.	1.1	348
459	Gastrointestinal Kaposi's Sarcoma in AIDS. <i>Journal of Clinical Gastroenterology</i> , 1984, 6, 165-172.	1.1	43
460	β -Blockade Therapy for Supraventricular Tachyarrhythmias After Coronary Surgery: A Propranolol Withdrawal Syndrome?. <i>Angiology</i> , 1979, 30, 816-819.	0.8	75
461	Hepatic Stellate Cell-Immune Interactions in NASH. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	30